Table 2.
Baseline characteristics of our participants who had magnetic resonance imaging scans compared to index study participants who did not have magnetic resonance imaging scans
|
Characteristic
|
Non-MRI scan group (n = 49)
|
MRI scan group (n = 39)
|
P
value
|
| Age, yr | 62 (58-68) | 62 (58-67) | 0.6 |
| Duration of type 2 diabetes, yr | 9 (4-12) | 8 (5-11) | > 0.9 |
| Insulin therapy, n (%) | 13 (26.5) | 5 (12.8) | 0.19 |
| Weight, kg | 102 (89-111) | 95 (90-104) | 0.12 |
| BMI, kg/m2 | 33.4 (31.2-35.9) | 31.5 (28.2-35.3) | 0.012 |
| Waist circumference, cm | 116 (109-123) | 111 (104-118) | 0.024 |
| Fat mass, g | 32696 (29299-39109) | 31832 (26820-37809) | 0.2 |
| Lean mass, g | 62004 (58056-66170) | 60,049 (54278-64848) | 0.12 |
| ALT, IU/L | 34 (25-50) | 32 (25-42) | 0.7 |
| ALP, IU/L | 71 (56-82) | 66 (54-75) | 0.2 |
| GGT, IU/L | 30 (24-43) | 32 (24-43) | 0.8 |
| TT, nmol/L (ECLIA) | 8.5 (7.3-10.5) | 8.1 (6.7-11.4) | 0.8 |
| cFT, pmol/L (ECLIA) | 176 (151-230) | 194 (148-253) | 0.6 |
| SHBG, nmol/L | 28 (24-32) | 29 (22-34) | > 0.9 |
| LH, IU/L | 4.5 (3.5-6.2) | 4.5 (3.4-6.4) | 0.9 |
| Fasting glucose, mmol/L | 8.2 (7.0-10.6) | 8.6 (7.3-9.9) | > 0.9 |
| HbA1c, % | 7.1 (6.6-7.7) | 6.9 (6.5-7.3) | 0.4 |
| Cholesterol, mmol/L | 4.1 (3.5-4.7) | 4.6 (4.0-4.9) | 0.005 |
| LDL, mmol/L | 2.0 (1.6-2.4) | 2.7 (2.0-3.1) | < 0.001 |
| HDL, mmol/L | 1.0 (0.9-1.2) | 1.1 (0.9-1.2) | 0.5 |
| SAT, cm3 | 4095 (3526-5593) | 4661 (3137-5385) | 0.7 |
| VAT, cm3 | 4786 (3,642-5,617) | 3634 (2780-4823) | 0.044 |
Data are median (IQR). MRI: Magnetic resonance imaging; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TT: Total testosterone; cFT: Calculated free testosterone; SHBG: Sex hormone-binding globulin; LH: Luteinising hormone; LDL: Low-density lipoprotein; HDL: High density lipoprotein; SAT: Subcutaneous adipose tissue; VAT: Visceral adipose tissue.